Cerebrolysin in Neurological Disorders: A Review of Clinical Applications

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Cerebrolysin is a porcine-derived compound composed of low molecular weight peptides and free amino acids with demonstrated neurotrophic and neuroprotective properties. It has been studied in a wide range of neurological conditions, including Alzheimer’s disease, vascular dementia, stroke, traumatic brain injury, Parkinson’s disease, multiple sclerosis, peripheral neuropathies, and migraine. This review outlines its mechanisms of action, constituent neuroactive components, and the current evidence supporting its clinical use.

Introduction

Cerebrolysin is a biologically active neuropeptide preparation that mimics the function of endogenous neurotrophic factors. These molecules are critical for neuronal survival, repair, and synaptic plasticity, thereby maintaining brain health and function. When neuronal damage occurs, either through disease or injury, exogenous administration of Cerebrolysin may substitute or supplement the brain’s diminished ability to produce its own neurotrophic factors.

Clinical and preclinical studies indicate that Cerebrolysin exerts both symptomatic benefits and disease-modifying effects, making it a potential therapeutic option for neurodegenerative and neurovascular conditions. Furthermore, evidence suggests a role in reducing the risk of cognitive decline among individuals genetically predisposed to Alzheimer’s disease.

Mechanistic Insights

Although the precise molecular pathways are not completely understood, several mechanisms of action have been proposed. Cerebrolysin appears to interact with neuronal receptors, including adenosine A1 and GABAb, exerting immunomodulatory effects that reduce inflammation associated with neurodegeneration.

Animal studies have demonstrated that Cerebrolysin penetrates the blood–brain barrier, with measurable concentrations across different brain regions. Its effects include reducing microglial activation, suppressing pro-inflammatory cytokines such as interleukin-1β, and modulating amyloid precursor protein processing, which reduces amyloid-β accumulation in Alzheimer’s pathology.

Additional effects include mimicking nerve growth factor activity on cholinergic neurons, upregulating glucose transporter GLUT1 expression to improve cerebral glucose availability, and supporting overall neuronal survival and plasticity.

Active Components

Cerebrolysin consists of biologically relevant peptides and proteins, including:

• Nerve Growth Factor (NGF): Essential for the development and maintenance of sensory neurons related to pain, temperature, and touch.
• Brain-Derived Neurotrophic Factor (BDNF): Critical for synaptic plasticity, learning, and memory.
• Ciliary Neurotrophic Factor (CNTF): Supports neuronal survival and axonal growth during development.
• Enkephalins: Endogenous opioids influencing pain perception and stress response.
• Orexin: Regulates arousal, sleep-wake cycles, metabolism, and appetite.
• P21 Fragment: Promotes neuronal plasticity and regeneration.

Clinical Evidence

Alzheimer’s Disease

Randomized controlled trials have demonstrated improvements in cognitive outcomes in patients with mild to moderate Alzheimer’s disease following intravenous administration. Notably, sustained benefits have been observed for up to six months after treatment. Preclinical studies further support a preventative role in genetically susceptible populations, such as those carrying the APOE4 allele.

Vascular Dementia

Studies indicate that patients with vascular dementia experience significant improvements in cognitive scales such as ADAS-cog and CIBIC+ after Cerebrolysin therapy. Unlike symptomatic treatments, its mechanism targets pathological cascades, offering potential disease-modifying effects.

Parkinson’s Disease

Experimental models suggest Cerebrolysin reduces oxidative stress and alpha-synuclein accumulation. In traumatic brain injury-associated Parkinsonian models, the combination of Cerebrolysin and stem cell therapy demonstrated synergistic neuroprotective effects.

Stroke Recovery

In ischemic stroke, Cerebrolysin combined with rehabilitation enhances motor recovery, especially in severely impaired patients. While results in hemorrhagic stroke have been less conclusive, treatment has been shown to be safe and well tolerated.

Peripheral Neuropathy and Multiple Sclerosis

Animal studies indicate that Cerebrolysin enhances nerve regeneration, increasing myelinated fiber density and myelin thickness. This highlights its potential in diabetic neuropathy and demyelinating conditions such as multiple sclerosis.

Migraine

Preclinical research suggests that Cerebrolysin reduces migraine-associated behaviors and decreases inflammatory mediators such as CGRP, PACAP, and TNF-α, pointing toward potential clinical application in chronic migraine management.

Conclusion

Cerebrolysin demonstrates a broad spectrum of neuroprotective and neurotrophic activity across multiple neurological conditions. Its capacity to mimic endogenous growth factors, reduce neuroinflammation, and enhance neuronal plasticity positions it as a promising adjunct in both acute recovery and chronic neurodegenerative disease management. Continued large-scale clinical trials are warranted to better define its therapeutic potential and long-term benefits.

REFERENCES

1. Boado R. J. (1996). Brain-derived peptides increase the expression of a blood-brain barrier GLUT1 glucose transporter reporter gene. Neuroscience letters, 220(1), 53–56. https://doi.org/10.1016/s0304-3940(96)13237-7
2. Alvarez, X. A., Cacabelos, R., Laredo, M., Couceiro, V., Sampedro, C., Varela, M., Corzo, L., Fernandez-Novoa, L., Vargas, M., Aleixandre, M., Linares, C., Granizo, E., Muresanu, D., & Moessler, H. (2006). A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. European journal of neurology, 13(1), 43–54. https://doi.org/10.1111/j.1468-1331.2006.01222.x
3. Plosker, G. L., & Gauthier, S. (2009). Cerebrolysin: a review of its use in dementia. Drugs & aging, 26(11), 893–915. https://doi.org/10.2165/11203320-000000000-00000
4. Allegri, R. F., & Guekht, A. (2012). Cerebrolysin improves symptoms and delays progression in patients with Alzheimer’s disease and vascular dementia. Drugs of today (Barcelona, Spain : 1998), 48 Suppl A, 25–41. https://doi.org/10.1358/dot.2012.48(Suppl.A).1739721
5. Gauthier, S., Proaño, J. V., Jia, J., Froelich, L., Vester, J. C., & Doppler, E. (2015). Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dementia and geriatric cognitive disorders, 39(5-6), 332–347. https://doi.org/10.1159/000377672
6. Dubový, P., Raška, O., Klusáková, I., Stejskal, L., Celakovský, P., & Haninec, P. (2011). Ciliary neurotrophic factor promotes motor reinnervation of the musculocutaneous nerve in an experimental model of end-to-side neurorrhaphy. BMC neuroscience, 12, 58. https://doi.org/10.1186/1471-2202-12-58
7. Mahmoudi, J., Mohaddes, G., Erfani, M., Sadigh-Eteghad, S., Karimi, P., Rajabi, M., Reyhani-Rad, S., & Farajdokht, F. (2018). Cerebrolysin attenuates hyperalgesia, photophobia, and neuroinflammation in a nitroglycerin-induced migraine model in rats. Brain research bulletin, 140, 197–204. https://doi.org/10.1016/j.brainresbull.2018.05.008

Bornstein, N. M., Guekht, A., Vester, J., Heiss, W. D., Gusev, E., Hömberg, V., Rahlfs, V. W., Bajenaru, O., Popescu, B. O., & Muresanu, D. (2018). Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 39(4), 629–640. https://doi.org/10.1007/s10072-017-3214-0